Bruce L Zuraw1, Aleena Banerji2, Jonathan A Bernstein3, Paula J Busse4, Sandra C Christiansen5, Mark Davis-Lorton6, Michael M Frank7, Henry H Li8, William R Lumry9, Marc Riedl10. 1. Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, Calif; Medicine Service, San Diego Veterans Administration Healthcare, San Diego, Calif. Electronic address: bzuraw@ucsd.edu. 2. Division of Allergy and Immunology, Department of Medicine, Harvard Medical School, Boston, Mass. 3. Division of Immunology/Allergy, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio. 4. Division of Clinical Immunology, Department of Medicine, Mount Sinai School of Medicine, New York, NY. 5. Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, Calif; Allergy Department, Southern California Kaiser Permanente, San Diego, Calif. 6. Division of Rheumatology & Immunology, Winthrop University Hospital, Mineola, NY. 7. Division of Pediatric Allergy and Immunology, Department of Pediatrics, Duke University Medical Center, Durham, NC. 8. Institute for Asthma and Allergy, Chevy Chase, Md. 9. Allergy and Asthma Specialists, Dallas, Tex. 10. Clinical Immunology and Allergy, Department of Medicine, University of California Los Angeles, Los Angeles, Calif.
Abstract
BACKGROUND: The treatment of hereditary angioedema (HAE) has undergone dramatic changes as newer medicines have become available in recent years. Optimal care of these patients requires a comprehensive management plan. Although several consensus papers have been published concerning the diagnosis and treatment of HAE, guidelines for a comprehensive management plan have not been developed. OBJECTIVE: To develop state-of-the-art recommendations for the treatment and management of HAE due to C1 inhibitor (C1INH) deficiency in the United States. METHODS: Members of the US Hereditary Angioedema Association Medical Advisory Board began by reviewing the literature concerning treatment of HAE. Preliminary recommendations were developed based on the literature review, discussions in a face-to-face meeting, and refinements in a series of drafts. Final recommendations reflect the unanimous consensus of the medical advisory board and the US Hereditary Angioedema Association leadership. RESULTS: Recommendations are provided regarding a comprehensive care plan for HAE, including the following: development of an overall management plan, treatment of angioedema attacks, prophylactic treatment, and patient monitoring. CONCLUSION: A comprehensive individualized management plan developed between an expert HAE physician and the patient, in collaboration with local medical providers and emergency departments, can provide patients with the best opportunity to lead a normal life.
BACKGROUND: The treatment of hereditary angioedema (HAE) has undergone dramatic changes as newer medicines have become available in recent years. Optimal care of these patients requires a comprehensive management plan. Although several consensus papers have been published concerning the diagnosis and treatment of HAE, guidelines for a comprehensive management plan have not been developed. OBJECTIVE: To develop state-of-the-art recommendations for the treatment and management of HAE due to C1 inhibitor (C1INH) deficiency in the United States. METHODS: Members of the US Hereditary Angioedema Association Medical Advisory Board began by reviewing the literature concerning treatment of HAE. Preliminary recommendations were developed based on the literature review, discussions in a face-to-face meeting, and refinements in a series of drafts. Final recommendations reflect the unanimous consensus of the medical advisory board and the US Hereditary Angioedema Association leadership. RESULTS: Recommendations are provided regarding a comprehensive care plan for HAE, including the following: development of an overall management plan, treatment of angioedema attacks, prophylactic treatment, and patient monitoring. CONCLUSION: A comprehensive individualized management plan developed between an expert HAE physician and the patient, in collaboration with local medical providers and emergency departments, can provide patients with the best opportunity to lead a normal life.
Authors: Aleena Banerji; Paula Busse; Sandra C Christiansen; Henry Li; William Lumry; Mark Davis-Lorton; Jonathan A Bernstein; Michael Frank; Anthony Castaldo; Janet F Long; Bruce L Zuraw; Marc Riedl Journal: Allergy Asthma Proc Date: 2015 May-Jun Impact factor: 2.587
Authors: Ting Qiu; Maria J Chiuchiolo; Adele S Whaley; Anthony R Russo; Dolan Sondhi; Stephen M Kaminsky; Ronald G Crystal; Odelya E Pagovich Journal: Allergy Date: 2019-03-19 Impact factor: 13.146
Authors: Aleena Banerji; Yu Li; Paula Busse; Marc A Riedl; Nicole S Holtzman; Huamin Henry Li; Mark Davis-Lorton; Jonathan A Bernstein; Michael Frank; Anthony J Castaldo; Janet Long; Bruce Zuraw; William Lumry; Sandra Christiansen Journal: Allergy Asthma Proc Date: 2018-05-01 Impact factor: 2.587
Authors: John Anderson; Donald S Levy; William Lumry; Patricia Koochaki; Sally Lanar; H Henry Li Journal: Allergy Asthma Clin Immunol Date: 2021-06-27 Impact factor: 3.406